Trial Profile
A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Inhaled AZD5423 After Single Ascending Doses in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs AZD 5423 (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors AstraZeneca
- 03 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 31 Aug 2009 New trial record